3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
40
Phase 1
32
Phase 2
23
Phase 1/2
20
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Interventions
Zoledronic Acid
23
Bevacizumab
13
nilotinib
12
Docetaxel
12
Paclitaxel
11
Everolimus
11
Letrozole
10
Imatinib Mesylate
10
Capecitabine
10
Erlotinib Hydrochloride
9
Drug Therapy
9
Carboplatin
9
pegfilgrastim
8
enzalutamide
8
Trastuzumab
7
Oxycodone
7
Nivolumab
7
Imiquimod
7
Gemcitabine
7
Epoetin Alfa
7
icotinib
6
Rituximab
6
Prednisone
6
Pemetrexed
6
Oxaliplatin
6
Leuprolide
6
Fulvestrant
6
Diclofenac
6
Dexamethasone
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
INDUSTRY
×
pomalidomide
×
Clear all
NCT05183139
2022-05-03
US MM-7
Takeda
Phase 4
Withdrawn